I get your point, and this may look good on paper at least. However, I expect the boards of CSL and RAC would be dealing with completely different types of problems and therefore their makeup and skill set would potentially differ significantly. Also, RAC having a board member from "Big Pharma" may not be ideal at this stage from a deal-making perspective.
I get your point, and this may look good on paper at least....
-
- There are more pages in this discussion • 52 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.65 |
Change
-0.080(4.64%) |
Mkt cap ! $292.1M | |||
| Open | High | Low | Value | Volume |
| $1.76 | $1.77 | $1.60 | $275.4K | 162.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 3990 | $1.64 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.70 | 950 | 1 |
View Market Depth
| Last trade - 15.05pm 23/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |